number 1: The futility of transvaginal ultrasound in type II endometrial cancer C. Billingsley, K. Kenne, C. Cansino, D. O'Malley, D. Cohn, J. Fowler, E. Eisenhauer, L. Copeland, F. Backes, R. Salani, The Ohio State University, Columbus, OH, USA, University of California Davis, Sacramento, CA, USA, University of Cincinnati, UC Health Medical Arts Building, Cincinnati, OH, USA Objectives: To determine the utility of transvaginal ultrasound (TVUS) in women with type II endometrial cancer, including serous, clear cell, and high-grade carcinomas. Methods: A retrospective review was conducted in women with pathology proven type II endometrial cancer that underwent preoperative TVUS. The following data were obtained: endometrial stripe (EMS) measurement, presence of intracavitary fluid or lesion, myometrial and/or adnexal masses, uterine size and volume. Pathology reports were reviewed and clinicopathologic factors were abstracted. Descriptive analyses were performed to assess demographic and comparative data. Results: Sixty-three women comprised the study cohort and the median age was 65 years. The most commonly reported symptom was postmenopausal bleeding in 51 patients (80.9%). The EMS was reported as thin (b5 mm) or indistinct in 18 patients (28.6%). Approximately 60% of patients were noted to have one or more ultrasound abnormalities: intracavitary lesion (18, 28.6%), intracavitary fluid (8, 12.7%), myometrial lesion (19, 30.2%), and adnexal mass (8, 12.7%). Poorly differentiated endometrioid cancer (33; 52.4%) represented the predominant histology. Of the 28% of women with a thin/indistinct EMS, seven women did not have an ultrasound abnormality, representing 11% of women with type II endometrial cancer who had no abnormal ultrasound findings whatsoever. Conclusions: Women with type II endometrial cancer were found to have a thin/indistinct EMS on TVUS in approximately 25% of cases. Furthermore, lack of any ultrasound abnormality, including a thickened EMS, were noted in 11% of patients. The use of TVUS, which has been of diagnostic and triaging value for women with type I cancer, is of limited utility in type II endometrial cancer. Therefore, endometrial sampling should be included in the evaluation of all women with postmenopausal bleeding, regardless of EMS thickness. doi:10.1016/j.ygyno.2014.04.019 Abstract number 2: Durationof intra-chemotherapy anemia is associatedwith prognosis and survival in epithelial ovarian cancer R. Brightwell, K. Eng, S. Lele, K. Odunsi, Roswell Park Cancer Institute,number 2: Durationof intra-chemotherapy anemia is associatedwith prognosis and survival in epithelial ovarian cancer R. Brightwell, K. Eng, S. Lele, K. Odunsi, Roswell Park Cancer Institute,